BioTuesdays

Tag - Danielle Antalffy

Minerva Surgical

Analysts start Minerva Surgical at OW, OP; PT $17

Piper Sandler and SVB Leerink launched coverage of Minerva Surgical (NASDAQ:UTRS) with “overweight” and “outperform” ratings, respectively, and price targets of $17. The stock closed at $9.62 on Nov. 15. Minerva, which...

Neuropace

SVB Leerink starts NeuroPace at OP; PT $25

SVB Leerink initiated coverage of Neuropace (NASDAQ:NPCE) with an “outperform” rating and $25 price target. The stock closed at $20.91 on May 14. “To us, NeuroPace represents a top-tier growth profile SMID-cap MedTech...

Neovasc Logo

SVB Leerink cuts Neovasc PT to $2 from $6

SVB Leerink slashed its price target for Neovasc (NASDAQ:NVCN) to $2 from $6, citing timing uncertainty for a U.S. launch of the company’s Reducer stent for percutaneous treatment of refractory angina. The stock closed...

Axonics Modulation Technologies

SVB Leerink starts Axonics Modulation at OP; PT $45

SVB Leerink initiated coverage of Axonics Modulation Technologies (NASDAQ:AXNX) with an “outperform” rating and $45 price target. The stock closed at $30.27 on Sept. 16. “To us, Axonics represents a hyper-growth story...

Leerink Logo

Leerink outlines 2018 outlook of healthcare shares

Leerink is recommending that healthcare investors, after a market-beating 2017, look for ways to keep up with what will likely be a strong broader stock market in 2018. “We encourage use of higher-beta healthcare and...